MO KEOVONGSA: Open Payments
NPI 1710157300 · BURLINGTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,425 in 109 payments from 23 companies in 2025. Trend: 2023 $116 · 2024 $3,920 · 2025 $2,425
Food & beverage: $2,425
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 23 | $386 |
| ABBVIE INC. | 18 | $340 |
| Regeneron Healthcare Solutions, Inc. | 6 | $288 |
| Gilead Sciences, Inc. | 9 | $210 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $172 |
| Madrigal Pharmaceuticals | 4 | $157 |
| PFIZER INC. | 8 | $152 |
| Janssen Biotech, Inc. | 6 | $139 |
| GENZYME CORPORATION | 5 | $131 |
| QOL Medical, LLC | 3 | $84 |
Products named: XIFAXAN, DUPIXENT, RINVOQ, REZDIFFRA, XELJANZ, TREMFYA, CREON, ENTYVIO.
Industry payments across MA — which companies pay providers there.
